29 results
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates
8-K
EX-1.1
HEPA
Hepion Pharmaceuticals Inc
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
”), the United Nations Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authorities, including, without … by European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); (iv) any information which would qualify as “protected health information” under
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates
8-K
EX-1.1
18mc60ef8bw 8xx54j0
12 Feb 20
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
wyit4mgqesppvo3b3w
19 Mar 19
Entry into a Material Definitive Agreement
4:56pm
10-KT
9tkhlek3c1nvl18ejv
26 Mar 18
Annual report (with FYE transition)
12:00am
424B5
2mq43jcacwpku
7 Oct 15
Prospectus supplement for primary offering
12:00am